Pfizer starts evaluation of SARS-CoV-2 oral antiviral

By The Science Advisory Board staff writers

Pfizer is advancing its clinical research of PF-07321332, a new investigational oral antiviral therapy against SARS-CoV-2, to evaluate the safety and efficacy of multiple ascending doses of the drug candidate.

PF-07321332 is the first orally administered novel coronavirus-specific investigational protease inhibitor to be evaluated in clinical studies, according to the company. The treatment can potentially be given as an oral therapy at the first signs of infection, without requiring that patients are hospitalized.

The announcement comes after the dosing of single ascending doses of the SARS-CoV-2-3CL protease inhibitor candidate was completed in healthy adults. PF-07321332 has demonstrated potent in vitro antiviral activity against SARS-CoV-2, as well as activity against other coronaviruses, suggesting its potential for use in treating COVID-19.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking